XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.26.1

NON-CONTROLLING INTEREST | 12 Months Ended
--- | ---
Mar. 31, 2026
Notes and other explanatory information [abstract] |
NON-CONTROLLING INTEREST | NOTE 24. NON-CONTROLLING INTEREST The table below summarize the Company’s non-controlling interest as of the periods presented (in thousands):
Schedule of non-controlling interest |  |  |  |
|  |  | Saugatuck and subsidary |
Non-controlling interest as of April 1, 2023 |  | $ | (650 | )
Net loss attributable to non-controlling interest |  |  | (43 | )
Non-controlling interest as of March 31, 2024 |  | $ | (693 | )
Net loss attributable to non-controlling interest |  |  | (11 | )
Non-controlling interest as of March 31, 2025 |  | $ | (704 | )
Net loss attributable to non-controlling interest |  |  | (1 | )
Non-controlling interest as of March 31, 2026 |  | $ | (705 | )
The Company held 70% interest in Saugatuck and subsidiary through SalvaRx. Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.

X
- Definition The entire disclosure for interests in other entities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 1 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_1&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NotesAndOtherExplanatoryInformationAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration